Physician

Will Rowland Voelzke, M.D.

According to 2025 Medicare claims, Will Voelzke, M.D. (NPI: 1023205697) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23235-4730.

Voelzke's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 853 traditional Medicare patients, billed 136,980 HCPCS/CPT codes, and received $3,145,905 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,332 prescription claims across 224 beneficiaries totaling $3,730,410 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 67 records totaling $3,297. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $864,848 to $3,730,410. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $10,834 to $2,627.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	927	168,206	$2,009,145
2016	927	160,375	$2,203,393
2017	1,013	197,089	$3,002,850
2018	1,068	264,585	$3,335,633
2019	1,048	197,314	$2,618,347
2020	934	143,914	$2,811,659
2021	873	134,417	$2,520,138
2022	855	131,536	$2,567,906
2023	837	131,921	$2,379,309
2024	853	136,980	$3,145,905

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	183	969	$864,848
2016	188	1,152	$1,180,124
2017	220	1,295	$1,475,313
2018	217	1,347	$1,524,412
2019	214	1,384	$1,753,879
2020	210	1,400	$2,087,076
2021	229	1,334	$2,478,931
2022	222	1,299	$2,938,353
2023	230	1,411	$2,762,054
2024	224	1,332	$3,730,410

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	47	337	$45,647
2016	N/R	107	$25,544
2017	N/R	38	$13,460
2018	N/R	60	$8,908
2019	N/R	11	$207
2020	N/R	N/R	N/R
2021	N/R	26	$2,077
2022	N/R	35	$978
2023	N/R	58	$6,959
2024	N/R	11	$599

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	118	395	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	311	783	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	357	523	$62
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	107	222	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	237	299	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	37	1,021	$661,213
Imbruvica	Ibrutinib	32	981	$516,299
Fotivda	Tivozanib Hcl	11	308	$340,934
Lenalidomide	Lenalidomide	17	476	$281,564
Jakafi	Ruxolitinib Phosphate	17	495	$253,398

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4385	Ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, without built-in convexity, each	N	N/R	11	$599

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	66	$1,536	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$1,762	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Will Rowland Voelzke, M.D.?

Tedicare shows public-source Medicare data for Will Rowland Voelzke, M.D. (NPI 1023205697), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Will Rowland Voelzke, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Will Rowland Voelzke, M.D.?

Will Rowland Voelzke, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Will Rowland Voelzke, M.D. have Open Payments data?

Will Rowland Voelzke, M.D. has 67 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.